eligibility_summary
Adults (≥18) with multiple myeloma, measurable disease (IMWG), ECOG ≤2, triple-class refractory to a proteasome inhibitor, IMiD, and anti‑CD38, and ≥1 therapy after TCR. Excludes acute plasma cell leukemia, amyloidosis, smoldering MM, stem cell transplant within 12 weeks or active GVHD, other active malignancy within 3 years (except basal/squamous skin or in situ), or investigational drug use within 30 days.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Elranatamab (PF-06863135), a bispecific IgG antibody immunotherapy, versus real‑world physician’s‑choice standard of care (SOC). Mechanism of action: Elranatamab simultaneously binds BCMA on multiple myeloma/plasma cells and CD3 on T cells, creating an immune synapse that activates T cells to kill BCMA+ tumor cells via cytotoxic granule release and cytokine‑mediated responses. Cells/pathways targeted: BCMA (TNFRSF17) on malignant plasma cells, CD3 on cytotoxic T lymphocytes with downstream T‑cell activation pathways. SOC comprises heterogeneous anti‑myeloma regimens with varied mechanisms.